1. Home
  2. Analysis
  3. Digoxin
  4. Idhifa

Digoxin and Idhifa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Digoxin (digoxin) and Idhifa (enasidenib mesylate). Common drug interactions include drug ineffective among females and decreased appetite among males.

The phase IV clinical study analyzes what interactions people have when they take Digoxin and Idhifa. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Digoxin?

Digoxin has active ingredients of digoxin. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 93,740 Digoxin users. Check the latest studies of Digoxin.

What is Idhifa?

Idhifa has active ingredients of enasidenib mesylate. eHealthMe is studying from 2,880 Idhifa users. Check the latest studies of Idhifa.

On Jul, 26, 2026

11 people who take Digoxin and Idhifa together, and have interactions are studied.

Digoxin and Idhifa drug interactions.

What are the common drug interactions of Digoxin and Idhifa, by gender? *:

female:

  1. Drug ineffective

male:

  1. Decreased appetite
  2. Platelet count decreased
  3. Fatigue (feeling of tiredness)
  4. Abdominal distension
  5. Arthralgia (joint pain)
  6. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  7. Cardiac disorder
  8. Hepatitis b
  9. Psoriasis (immune-mediated disease that affects the skin)
  10. Thrombosis (formation of a blood clot inside a blood vessel)

What are the common drug interactions of Digoxin and Idhifa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Decreased appetite
  2. Platelet count decreased
  3. Abdominal distension
  4. Arthralgia (joint pain)
  5. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  6. Cardiac disorder
  7. Death
  8. Hepatitis b
  9. Psoriasis (immune-mediated disease that affects the skin)
  10. Thrombosis (formation of a blood clot inside a blood vessel)

What are the existing conditions these people have? *

  1. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 9 people, 81.82%
  2. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 9.09%
  3. Breast Cancer Female: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Digoxin and Idhifa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Digoxin and Idhifa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Digoxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Idhifa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Digoxin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Idhifa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on digoxin and enasidenib mesylate (the active ingredients of Digoxin and Idhifa, respectively), and Digoxin and Idhifa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.